AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate for multiple cancer types.

Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024